Zentalis Pharmaceuticals Announces $25 Million Equity Investment From Pfizer
PUBLIC · ZNTLApr 27, 2022
Amount Raised
$25 Million
Round Type
Venture
San DiegoBiotechnologyHealthcareMedicalTherapeuticsPharmaceuticalresearch
Description
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that it has agreed to sell 953,834 of its common shares at a price of $26.21 per share to Pfizer for gross proceeds of $25.0 million (the “Transaction”). The common shares were offered and sold to Pfizer in a registered direct offering conducted without an underwriter or placement agent. The offering is expected to close on or about April 29, 2022, subject to customary closing conditions
Company Information
Company
Zentalis Pharmaceuticals
Location
10275 Science Center Dr
San Diego, California, United States
About
Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC.
Fundz sees it the moment Zentalis Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San DiegoBiotechnologyHealthcareMedicalTherapeuticsPharmaceuticalresearch